Calprotectin: from biomarker to biological function

A Jukic, L Bakiri, EF Wagner, H Tilg, TE Adolph - Gut, 2021 - gut.bmj.com
The incidence of inflammatory bowel diseases (IBD) emerged with Westernisation of dietary
habits worldwide. Crohn's disease and ulcerative colitis are chronic debilitating conditions …

European guideline on obesity care in patients with gastrointestinal and liver diseases–Joint European Society for Clinical Nutrition and Metabolism/United European …

SC Bischoff, R Barazzoni, L Busetto… - United European …, 2022 - Wiley Online Library
Background Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux …

[HTML][HTML] Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing crohn's …

D Garcia-Olmo, I Gilaberte, M Binek… - Diseases of the Colon …, 2022 - ncbi.nlm.nih.gov
BACKGROUND: Darvadstrocel is an expanded allogeneic adipose-derived mesenchymal
stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn's …

[HTML][HTML] European guideline on obesity care in patients with gastrointestinal and liver diseases–Joint ESPEN/UEG guideline

SC Bischoff, R Barazzoni, L Busetto… - Clinical Nutrition, 2022 - Elsevier
Background Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux …

Inflammatory bowel disease–non-biological treatment

F Magro, G Cordeiro, AM Dias, MM Estevinho - Pharmacological Research, 2020 - Elsevier
Nowadays, non-biological treatments remain valuable approaches among the therapeutic
armamentarium of inflammatory bowel disease (IBD). Mesalamine is the core treatment of …

Treatment algorithms for Crohn's disease

MC Sulz, E Burri, P Michetti, G Rogler, L Peyrin-Biroulet… - Digestion, 2020 - karger.com
Background: Treatment of Crohn's disease (CD) patients is complex as therapy choices
depend on a variety of factors, such as location and severity of inflammation, disease …

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn “der Deutschen Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten …

A Sturm, R Atreya, D Bettenworth… - Zeitschrift für …, 2022 - thieme-connect.com
Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

Nutritional treatment in Crohn's disease

G Caio, L Lungaro, F Caputo, E Zoli, F Giancola… - Nutrients, 2021 - mdpi.com
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) which can affect any
part of the whole gastrointestinal tract (from mouth to anus). Malnutrition affects 65–75% of …

[HTML][HTML] Surgical management of Crohn's disease: A state of the art review

EM Meima-van Praag, CJ Buskens, R Hompes… - International Journal of …, 2021 - Springer
Purpose The aim of this review was to examine current surgical treatments in patients with
Crohn's disease (CD) and to discuss currently popular research questions. Methods A …

Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre …

C Loras, X Andújar, JB Gornals, V Sanchiz… - The Lancet …, 2022 - thelancet.com
Background Endoscopic balloon dilation (EBD) is the established endoscopic treatment for
short strictures in Crohn's disease. Fully covered self-expandable metal stents (FCSEMS) …